X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

Astellas and KM Biologics Expiration of Distribution Agreement for Human Vaccines, etc. and Blood Plasma Products

Content Team by Content Team
24th January 2019
in Press Statements, Research & Development
Astellas and KM Biologics Expiration of Distribution Agreement for Human Vaccines, etc. and Blood Plasma Products

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Astellas Pharma Inc and KM Biologics Co., Ltd. announced that the agreement for the distribution by Astellas of human vaccines, etc. and blood plasma products , which KM Biologics manufactures and sells in Japan, will expire on July 31, 2019. In accordance with the expiration of the agreement, distribution of the products will be transferred as follows.

In terms of human vaccines, etc., Meiji Seika Pharma Co., Ltd. (“Meiji Seika Pharma”), which is an affiliate of Meiji Holdings Co., Ltd. same as KM Biologics, will distribute them as soon as, after April 2019, Astellas’ inventory of those products runs out, based on the distribution agreement concluded by KM Biologics with Meiji Seika Pharma. Meanwhile, Meiji Seika Pharma will provide and collect information on the products from medical institutions from April 1, 2019.

In terms of blood plasma products, Japan Blood Products Organization (“JB”) will distribute them, and provide and collect information on those products from medical institutions from August 1, 2019, based on the distribution agreement concluded by KM Biologics with JB.

Astellas and KM Biologics will work closely with Meiji Seika Pharma and JB to ensure a smooth transfer of the distribution of the products to continue delivering them to patients stably.

List of the major products
“Human vaccines, etc.”
Influenza HA Vaccine “KMB”, Quattrovac, ENCEVAC, Bimmugen,
Aimmugen, Inactivated Tissue Culture Rabies Vaccine,
and Freeze-dried Mamushi Antivenom “KMB”, etc.

“Blood plasma fraction Formulations”
BOLHEAL®, Confact® F, Novact® M, etc.

Sales of the Products by Astellas (Fiscal year ended March 31, 2018)
Approximately 24 billion yen (gross sales basis)

About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people
around the world through the provision of innovative and reliable pharmaceutical products. For more
information, please visit our website at https://www.astellas.com/en

About KM Biologics
KM Biologics Co., Ltd. is a Kumamoto (Japan) based company that supplies high-quality biological
products and services to create a healthy future for people all around the world.
Please visit our website for more information: http://www.kmbiologics.com/en/

Previous Post

TrakCel and Quick partner to provide Digital Supply Chain IT solution for Cell and Gene Therapies

Next Post

TC BioPharm creates allogeneic cell banks for CAR T cancer therapy products

Related Posts

Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
wearable drug delivery devices
Insights

Wearable Drug Delivery Devices for On-Demand Care

27th September 2025
biologic drug formulation stability
Drug Development

Breakthroughs in Biologic Drug Formulation Stability

27th September 2025
high volume injectable formulations
Insights

Overcoming Challenges in High-Volume Injectable Formulations

27th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
Next Post
TC BioPharm creates allogeneic cell banks for CAR T cancer therapy products

TC BioPharm creates allogeneic cell banks for CAR T cancer therapy products

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In